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Summary The management of dry mouth is essential for patients with Sjo¨gren’s syndrome. The
symptomatic treatment has included using air humidifiers, rinsing the mouth with water or
mouthwash, the application of a salivary substitute and administration of secretagogues. There
are three secretagogues suitable for the alleviation of dry mouth in Sjo¨gren’s syndrome patients
in Japan; cevimeline hydrochloride hydrate (cevimeline), pilocarpine hydrochloride, and
anetholtrithione. A relationship between the effect of cevimeline on saliva secretion and the
degree of salivary gland destruction evaluated by sialography and histopathological findings in the
labial minor salivary glands has been reported. These diagnostic approaches could provide useful
prognostic information on the efficacy of cevimeline in Sjo¨gren’s syndrome patients. Concomi-
tantly, a bite guard was suggested as an effective lubricating device because it maintains the
lubricants in the proper location. In addition, the management of the complications of dry mouth,
such as tooth caries, periodontitis and oral candidiasis, which all lead to a reduction in the QOL, is
also important. Both the prevention and treatment of erythematous candidiasis is especially
important in the management of Sjo¨gren’s syndrome.
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116 Y. NakagawaIntroduction
Sjo¨gren’s syndrome is an autoimmune disease which shows
exocrinopathies characterized by lymphocytic infiltration into
the salivary and lacrimal glands resulting in dry mouth and dry
eyes [1]. The Committee on Sjo¨gren’s Syndrome of the Ministry
of Health and Welfare of Japan proposed the revised diagnostic
criteria for Sjo¨gren’s syndrome in 1999 [2]. The criteria consist
of 4 examinations; histopathology, and oral, ocular, and ser-
ological examinations, and does not include subjective eva-
luation of the symptoms. Although the revised Japanese
criteria are widely used in Japan as the diagnostic guideline,
clinicians often refer to the Sjo¨gren’s syndrome criteria pro-
posed by the American-European consensus group to make a
diagnosis [3]. Of the 2269 patients who attended the Dry Mouth
Clinic at Tsurumi University Dental Hospital with the complaint
of a dry mouth sensation from November 2002 to April 2007,
159 (7.0%) were diagnosed with Sjo¨gren’s syndrome [4]. These
results demonstrated that the causes of dry mouth were
various, and that Sjo¨gren’s syndrome existed in less than
10% of the dry mouth cases, thus, the importance of examina-
tions for the diagnosis was emphasized.
Xerostomia is defined as a subjective complaint of dry
mouth [5], and is caused by hyposalivation and/or hyper-
evaporation of saliva. Hyposalivation occurs due to various
causes, such as Sjo¨gren’s syndrome, radiation therapy to the
head and neck, the use of medications, and diabetes mellitus
[5]. Evaporation of saliva is mainly caused by mouth opening
or mouth breathing, which often occurs during the night
without an apparent decrease in the salivary flow. Evapora-
tion occurs even in the Sjo¨gren’s syndrome patients. Thus, for
the management of xerostomina in those with Sjo¨gren’s
syndrome, it is important not only to promote saliva secretion
and moisturize the oral mucosa, but also to prevent the
evaporation of saliva.
Saliva production and secretion is vital for the mainte-
nance of oral health and oral function. Common complica-
tions include rampant dental caries, candidiasis, mucosal
atrophy and burning, difficulty in denture retention and
use, compromised speech and swallowing, and reduced or
altered taste sensation [6]. The management of oral candi-
diasis has been recognized to be an especially important issue
in patients with Sjo¨gren’s syndrome. This will be discussed as
one of the topics, in addition to the management of dry
mouth, in this review.Management of dry mouth
Overview
The management of dry mouth has included using air humi-
difiers, rinsing the mouth with water or mouthwash, the
application of a salivary substitute and administration of
secretagogues. A large number of systemic agents have been
proposed as secretagogues, but only a few have shown con-
sistent salivary enhancing properties in well-designed, con-
trolled trials [7]. There are currently three secretagogues
suitable for alleviation of dry mouth in Sjo¨gren’s syndrome
patients in Japan; cevimeline hydrochloride hydrate (cevi-
meline), pilocarpine hydrochloride, and anetholtrithione.
Recently, the usefulness of a reservoir bite guard [8] and
an intraoral lubricating device [9—11] were reported to
deliver a saliva substitute to the oral cavity for hyposalivation
patients. We previously applied a simple bite guard for sleep-
related xerostomia [12], and based on the results of this
study, the bite guard is expected to alleviate dry mouth in
patients with Sjo¨gren’s syndrome.
Prediction of the efficacy of cevimeline in
patients with Sjo¨gren’s syndrome
Effects of cevimeline on salivation
Cevimeline, which is an agonist of muscarinic types 1 and 3
receptors [13], has shown clinical efficacy in increasing saliva
production and improving the subjective perception of oral
dryness in Sjo¨gren’s syndrome patients [14,15]. Sjo¨gren’s
syndrome leads to the loss of salivary acinar cells, and
secretagogues are thought to enhance salivation from the
remaining functional acinar cells. It can thus be hypothesized
that there would be a decreased effect of cevimeline in
patients with greater salivary gland tissue damage. In addi-
tion, autoantibodies that bind to muscarinic type 3 receptors
(M3R) were detected in the sera obtained from Sjo¨gren’s
syndrome patients [16], and IgG in patients with primary
Sjo¨gren’s syndrome was observed to reduce the carbachol-
evoked increase in Ca2+ in both mouse and human acinar
cells, showing that IgG from patients with primary Sjo¨gren’s
syndrome contains autoantibodies capable of damaging sal-
iva production [17]. These studies suggest the involvement of
autoantibodies to the receptors in the response to cevimeline
in patients with Sjo¨gren’s syndrome. Therefore, the clinical
Figure 1 The effects of cevimeline on whole stimulated sia-
lometry. Thirty consecutive Japanese female primary Sjo¨gren’s
syndrome patients with a mean age of 62.3  11.2 (range 22—78
years) treated with cevimeline for their dry mouth at the Tsurumi
University Dental Hospital Dry Mouth Clinic were enrolled in this
study. The diagnosis of Sjo¨gren’s syndrome was based on the
revised diagnostic criteria for Sjo¨gren’s syndrome by the Com-
mittee on Sjo¨gren’s syndrome of the Ministry of Health and
Welfare of Japan [2] and the Sjo¨gren’s syndrome criteria pro-
posed by the American-European consensus group [3]. Whole
stimulated sialometry (WSS) was determined by measuring a
volume of stimulated whole saliva, which was stimulated by
chewing a piece of gum (Free zone gum, Lotte Co., Ltd., Tokyo,
Japan). WSS was compared between the pre- and post-treatment
points (4 weeks after cevimeline administration) and the incre-
ment rate was also calculated by dividing the post-treatment
value by the pre-treatment value. Sialography of the unilateral
parotid gland was performed once before treatment with cevi-
meline using the conventional hand-injection method. A lateral
projection was taken immediately after injection of 1 ml of
contrast medium (76% diatrizoate sodium, Urografin: Nihon
Schering Co., Ltd., Osaka, Japan) into the Stensen’s duct. After
the addition of 0.5 ml of contrast medium, a posterior—anterior
radiograph was taken. Two trained examiners evaluated the
sialography in all cases according to the classification of Rubin
and Holt [53]: Stage 0, normal; Stage I, punctate; Stage II,
globular; Stage III, cavitary; and Stage IV, destructive. Stages
I—IV were considered to be positive according to the Sjo¨gren’s
syndrome criteria. Biopsy specimens were obtained from nor-
mal-appearing lower labial mucosa. Three trained pathologists
evaluated the focal lymphocytic sialoadenitis in the minor sali-
vary glands by hematoxylin and eosin (HE) staining according to
Greenspan’s criteria [54]: Grade 0, absent; Grade 1, slight
infiltrate; Grade 2, moderate infiltrate or less than one focus
per 4 mm2; Grade 3, one focus per 4 mm2; and Grade 4, more
than one focus per 4 mm2. Grades 3 and 4 were considered to be
positive according to the Sjo¨gren’s syndrome criteria. (A) Clas-
sification of sialography. (B) Classification of the labial minor
salivary gland biopsy. Data show the means  SD (open column:
pre-WSS, closed column: post-WSS). *p < 0.05, **p < 0.01.
Management of dry mouth in Sjo¨gren’s syndrome 117effect of cevimeline on the enhancement of salivary secre-
tion thus appears to be influenced multifactorially. If the
efficacy of cevimeline could be predicted from the findings of
diagnostic clinical examinations before treatment, it would
be useful for determining the prognosis of patients with
Sjo¨gren’s syndrome, and for determining whether another
therapy should be selected. Therefore, we previously con-
ducted a study to elucidate the relationship between the
effect of cevimeline and the findings of diagnostic clinical
examinations in patients with Sjo¨gren’s syndrome [18].
The relationship between the pre-treatment saliva
flow rate and the findings of diagnostic clinical
examinations
The relationship between the pre-treatment sialometry (sal-
iva flow rate) and clinical examination was the first to be
studied. Patients with positive sialography findings (Stages I—
IV) had significantly lower pre-treatment whole stimulated
sialometry (WSS) findings compared to those with negative
findings (Stage 0) ( p = 0.003) (Fig. 1A, open column). In
contrast, findings of labial minor salivary gland biopsy were
not related to pre-treatment WSS in patients with Sjo¨gren’s
syndrome ( p = 0.806) (Fig. 1B, open column). As WSS is
principally secreted from the parotid gland [19], this dis-
crepancy might be due to the differences in the evaluation
site (parotid gland versus minor salivary gland). These results
are congruent with those reported by Saito et al. [20].
Changes of the saliva flow rate after administration of
cevimeline
Fig. 1A shows the pre- and post-treatment WSS in groups
classified according to the sialography findings. In both the
Stage 0 and the Stages I—IV groups, the post-treatment WSS
demonstrated a significant increase compared with the pre-
treatment values ( p = 0.008 and p = 0.015, respectively). The
magnitude of the increase in WSS after cevimeline treatment
in the Stage 0 group was significantly higher than that in the
Stages I—IV group ( p < 0.001). The increment rate of WSS
after cevimeline treatment in the Stage 0 group was signifi-
cantly higher than that in the Stages I—IV group ( p = 0.042).
Fig. 1B shows the pre- and post-treatment WSS in groups
classified according to the findings of the labial minor salivary
gland biopsy. In both the Grades 0—2 and the Grades 3 and 4
groups, post-treatment WSS demonstrated a significant
increase compared to the pre-treatment values ( p = 0.018
and p = 0.006, respectively). However, the increment rate of
WSS after cevimeline treatment in the Grades 0—2 group was
significantly higher than that in the Grades 3 and 4 group
( p = 0.002). Similar findings [21] were reported for the use of
pilocarpine, a cholinergic parasympathomimetic agent,
which has shown efficacy in treating dry mouth symptoms
in Sjo¨gren’s syndrome patients [22,23].
Since both sialography and biopsy showed an increase in
the increment rates of WSS, and thereafter the relative
influence of the various clinical and immunological factors,
which are the examinations for diagnosis of Sjo¨gren’s syn-
drome, on the increase of WSS were next analyzed. A multi-
ple regression analysis was employed to examine the relative
contributions of the sialography stage, grade of lip biopsy,
and titer of anti-La/SS-B antibodies to the post-treatment
WSS (Table 1). It was thus demonstrated that the post-
treatment WSS could be predicted by the model(R2 = 0.880): Post-treatment WSS = 5.784 + (0.847  pre-
treatment WSS)  (0.869  grade of lip biopsy)  (0.867  -
stage of sialography)  (0.001  anti-La/SS-B antibody),
and that the stage classification of sialography ( p = 0.004)
and the histological grade of the labial minor salivary gland
biopsy ( p = 0.003) were significantly associated with the
post-treatment WSS.
Table 1 Results of multiple regression analysis to examine factors influencing the objective variable of post-treatment whole
stimulated sialometry.
Coefficient (b) SE Standardized coefficient (b) p-Value
Intercept 5.784 1.126 <0.001
WSS before treatment 0.874 0.100 0.707 <0.001
Grade of lip biopsy 0.869 0.269 0.232 0.003
Stage of sialography 0.867 0.269 0.259 0.004
SS-B 0.001 0.003 0.014 0.847
A multiple regression analysis was employed to examine the relative contributions of the clinical and immunological factors including age,
pre-treatment whole stimulated sialometry (WSS), duration of disease, sialography, minor salivary gland biopsy, anti-Ro/SS-A antibodies,
anti-La/SS-B antibodies, and antibodies to muscarinic type 3 receptors to the post-treatment WSS.
WSS: whole stimulated sialometry; Lip biopsy: labial minor salivary gland biopsy; SS-B: anti-La/SS-B antibodies.
Figure 2 Night guard for sleep-related xerostomia. The night
guard was fabricated with a soft material. The 1.5-mm-thick
ethylene vinyl acetate sheet (Sof-Tray Sheets, Ultradent Pro-
ducts, Inc., South Jordan, UT) was heated and aspirated to
secure the model using a vacuum forming system (Dental Sta-
Vac Model; Buffalo Dental Manufacturing, Syosset, NY). (A) The
night guard covered the dental arch and the hard palate, and did
not possess a reservoir for retaining a saliva substitute. (B)
Patients can use the device to maintain the presence of lubri-
cants.
118 Y. NakagawaOur preliminary results demonstrated the relationship
between the effect of cevimeline on saliva secretion and
the degree of salivary gland destruction as evaluated by
sialography and histopathological findings in the labial minor
salivary glands. These diagnostic approaches could provide
useful prognostic information about the efficacy of cevime-
line in Sjo¨gren’s syndrome patients. To verify the results in
the present study, a placebo-controlled, double blind rando-
mized trial will need to be performed.
Saliva substitutes and the use of a bite guard
Saliva substitutes
When saliva production cannot be stimulated by secretago-
gues, symptomatic management should be attempted. Var-
ious artificial saliva and saliva substitutes (lubricants) have
been used. There are three main types of saliva substitutes;
gels, mouth rinses, and sprays [24,25]. Gel type lubricants
can be effectively used in combination with a bite guard.
Application of a bite guard
Sleep-related xerostomia is a sensation of dry mouth asso-
ciated with a report of either mouth and/or throat discomfort
that induces awakening for water intake [26,27]. We applied a
simple bite guard for patients with sleep-related xerostomia
[12]. The device, fabricated with a soft material, is often used
as a sports mouth guard or as a night guard for the treatment of
nighttime bruxism. The 1.5-mm-thick ethylene vinyl acetate
sheet (Sof-Tray Sheets, Ultradent Products, Inc., South Jordan,
UT) was heated and aspirated to secure the model using a
vacuum forming system (Dental Sta-Vac Model; Buffalo Dental
Manufacturing, Syosset, NY). The bite guard covered the
dental arch and the hard palate, and did not possess a reservoir
for retaining the saliva substitute (Fig. 2A). The treatment
group of patients all used a bite guard during the night.
The subjective symptoms were assessed using a question-
naire before and after the 2-week treatment. The question-
naire was composed of 2 parts: a general impression (Fig. 3)
and a visual analogue scale (VAS) (Table 2). Following the
completion of the 2-week treatment, a substantial improve-
ment was reported by the treatment group (Fig. 3). The post-
treatment VAS value was significantly decreased compared
with that of the pre-treatment period in sensation of oral
dryness, thirstiness, and burning sensation of the tongue in the
treatment group (Table 2).
A hypothesis was proposed that unconscious episodes of
rhythmic masticatory muscle activity play an important rolein lubricating the oral cavity [26,27] and that the night guard
could help to regulate appropriate rhythmic muscle activity.
A second possible mechanism for nocturnal xerostomia
improvement with the night guard is maintenance of saliva
volume in the oral cavity. It was suggested that patients
Figure 3 Comparison of the improvement in the general im-
pression between the treatment and control groups. Fourteen
patients (7 males and 7 females; mean age 66.5  9.2, range:
55—93 years) were allocated to the treatment group, while 14
patients (7 males and 7 females; mean age 73.1  10.0, range:
54—78 years) were allocated to the control group. The control
group used a mouth rinse 3 times daily (morning, daytime and
before going to bed). Sodium azulene sulfonate is a water-
soluble derivative of azulene, which is an anti-inflammatory
component of chamomile of the family of Asteraceae. Sodium
azulene sulfonate has been clinically used as a therapeutic agent
in the treatment of pharyngitis as well as other inflammatory
diseases such as tonsillitis, stomatitis, and conjunctivitis [55,56],
but it has not been recognized to help in the alleviation of oral
dryness. There were no significant differences between the
groups in terms of age, whole resting sialometry (WRS), and
whole stimulated sialometry (WSS) by the Mann—Whitney test at
the pre-treatment period. The participants complained of noc-
turnal oral dryness, but they showed normal salivation during the
examination at the clinic. No factors that cause nocturnal
hyposalivation, such as medication side effects, could be identi-
fied. The patients did not show any signs of damage to their oral
cavity. Following completion of the 2-week treatment, the
general impression was scaled using 5 levels: 3, extremely
improved; 2, improved; 1, improved a little; 0, unchanged;
1, deteriorated (Mann—Whitney test). In the treatment group,
10 of the 14 patients (71%) showed improvement in their symp-
toms, but 4 indicated that their symptoms were unchanged. No
patients experienced an aggravation or worsening of symptoms.
Table 2 Comparison of the VAS between the treatment and
control groups.
p-Value
Treatment
group
Control
group
Sensation of oral dryness 0.0295 0.0942
Thirstiness 0.0012 0.3013
Stickiness in the oral cavity 0.0640 0.4961
Change of taste 0.2500 0.0547
Burning sensation of
the tongue
0.0371 0.8501
The Wilcoxon signed rank test was used to compare the visual
analogue scale (VAS) between pre- and post-treatment periods.
The post-treatment VAS value was significantly decreased com-
pared with that of the pre-treatment period in terms of the
sensation of oral dryness, thirstiness, and burning sensation of
the tongue in the treatment group. The sensation of dryness was
improved in all but two of the patients in the treatment group.
Management of dry mouth in Sjo¨gren’s syndrome 119recognized the sensation of dryness when there was not
enough saliva to cover the various oral surfaces, especially
the palate [28]. A third possible factor could be that the night
guard decreases the vaporization of saliva from the oral
cavity, which is dependent upon how long the mouth is open.
The night guard possibly prevents mouth opening, which
occurs due to malocclusion, nasal congestion, and enlarged
adenoids.
We concluded that the application of a bite guard is
therefore a useful and simple method for the management
of nocturnal xerostomia. Furthermore, the device can be
used not only during the night, but also during the daytime.
Dry mouth patients can use this device to maintain the
presence of artificial gel type lubricants in the mouth
(Fig. 2B). As a result, such a bite guard could also be useful
for Sjo¨gren’s syndrome patients.Immunological treatment for primary Sjo¨gren’s
syndrome
Immunological management is one of the options for patients
who do not respond to secretagogues or moisturizing saliva
substitutes with or without the bite guard. However, no trials
concerning the immunological treatment of primary Sjo¨g-
ren’s syndrome, such as interferon-alpha [29,30] and anti CD
antibodies [31—33] have been conducted so far in Japan,
although interferon-alpha and anti CD20 antibody were
recognized to be an effective and safe treatment strategy
for patients with primary Sjo¨gren’s syndrome in double-blind
placebo-controlled clinical trials [30,33,34]. Furthermore,
no clinicians in Japan have accepted even systemic admin-
istration of corticosteroids for the primary Sjo¨gren’s syn-
drome patients, and thus, the corticosteroid irrigation of
the parotid gland is the only currently available immunolo-
gical treatment option [35].
Depression and Sjo¨gren’s syndrome
Acute stress, such as anger and anxiety induce dry mouth
even for healthy people. Chronic psychological and psychia-
tric factors including anxiety and depression are related to
the occurrence of dry mouth sensation [36—38]. It is reported
that when evaluating the causes of the sensation of dry
mouth, the possibility of depression as an underlying factor
should be considered [36]. Furthermore, the unstimulated
salivary flow rate was negatively associated with the state of
anxiety [39].
When the correlation between the saliva flow rate and
the depression score using the Hospital Anxiety and Depres-
sion Scale (HADS) was examined, according to the data from
the Dry Mouth Clinic at Tsurumi University Dental Hospital,
the volume of whole resting sialometry (WRS) was signifi-
cantly decreased in the high score group (Group 3, p < 0.01)
in comparison to the lower score groups (Group 1 or 2)
(Fig. 4A). Similarly, a decrease in the volume of WSS was
observed in the patients in Group 3 on the depression scale
(Fig. 4B, p < 0.05). HADS is a self-assessment scale that was
Figure 4 The relationship between the saliva flow rate and the
depression scale. The patients were divided into 3 groups accord-
ing to the obtained HADS score: Group 1, score 0—7; Group 2,
score 8—10; Group 3, score 11—21. The HADS is a self-assessment
scale that was developed as an instrument for screening for
clinically significant anxiety and depression in patients attending
a general medical clinic [40]. The questionnaire is composed of 7
items on the anxiety scale and 7 items on the depression scale.
Anxiety and depression are both rated on four-point (0—3)
scales. (A) The relationship between whole resting sialometry
(WRS) and the depression scale score. (B) The relationship
between whole stimulated sialometry (WSS) and the depression
scale score. The values are expressed as the means  SE.
*p < 0.05, **p < 0.01.
Table 3 Contributions of the HADS score, age, sex, and medication
analysis.
Crude odds
ratio
95% CI 
Sex (male/female) 2.239 1.570—3.193
Age 1.033 1.022—1.045
Depression (negative/positive) 1.574 1.302—1.904
Anxiety (negative/positive) 1.042 0.871—1.247
Central nervous system 1.188 1.063—1.328
Cardiovascular medicine 1.277 1.045—1.561
Gastrointestinal medicine 1.177 1.002—1.382
Respiratory medicine 1.201 0.747—1.931
Anti-allergic medicine 1.283 0.676—2.434
Other medication 1.101 0.993—1.220
A logistic regression analysis was performed to calculate the crude an
120 Y. Nakagawadeveloped as an instrument for screening for clinically sig-
nificant anxiety and depression in patients attending a gen-
eral medical clinic [40]. A logistic regression analysis was
performed to calculate the crude and multivariate adjusted
odds ratios (Table 3). The results showed that a positive
score on the depression scale was associated with a decrease
in resting salivary flow, with a multivariate adjusted odds
ratio of 1.697, even when the effects of age (odds ratios
1.032, p < 0.001), gender (odds ratios 2.899, p < 0.001),
and medications were taken into account (Table 3). Simi-
larly, a positive score on the depression scale was associated
with decreased WSS, with a multivariate adjusted odds ratio
of 1.423 (data not shown). In contrast, a positive score on the
anxiety scale showed a tendency to increase the resting
salivary flow with a multivariate odds ratio of 0.787. These
results indicated that a positive score on the depression
scale was a risk factor for decreased salivary flow rates. Of
note, patients with primary Sjo¨gren’s syndrome had signifi-
cantly higher scoring rate for clinical anxiety and for clinical
depression compared with reference groups [41]. Studies
have indicated that patients with primary Sjo¨gren’s syn-
drome often have psychiatric symptoms and worse overall
well-being, which may affect their quality of life.
If psychiatric factors at least partially underlie the phy-
sical symptoms of Sjo¨gren’s syndrome, the management of
anxiety and/or depression is important. For such patients,
central nervous system agents including antidepressants and
anxiolytics are regarded as effective. Thus, the adequate use
of central nervous system agents may lead to the improve-
ment of dry mouth sensation due to hyposalivation, although
such agents may have side effects that include dry mouth.
Further studies are therefore needed to verify the efficacy of
such treatments for Sjo¨gren’s syndrome patients.
Management of oral candidiasis
Hyposalivation and oral candidiasis
Candidiasis is an opportunistic infection. Factors that can
increase the susceptibility to candidiasis include AIDS, phar-
yngeal radiation therapy, impaired granulocyte function,
long-term antibiotic therapy and a reduced saliva flow rates to the resting salivary flow according to the logistic regression
p-Value Multivariate
adjusted
odds ratio
95% CI p-Value
 <0.001 2.899 1.969—4.268 <0.001
 <0.001 1.032 1.020—1.045 <0.001
 <0.001 1.697 1.340—2.148 <0.001
 0.650 0.787 0.629—0.986 0.037
 0.002 1.064 0.937—1.209 0.340
 0.017 1.233 0.977—1.555 0.077
 0.047 0.976 0.812—1.173 0.795
 0.449 1.158 0.707—1.896 0.561
 0.445 1.325 0.675—2.602 0.413
 0.068 0.983 0.870—1.110 0.780
d multivariate adjusted odds ratios.
Figure 5 A histogram of the distribution frequency in each
level of Candida CFU level. The patients analyzed in this study
included 127 males and 551 females, with a mean age of 62.5,
ranging from 4 to 92 years old. The patients were divided into 2
groups according to the presence of erythematous signs; positive
(+) and negative (). The histogram demonstrated the differ-
ences in patient distribution between the two groups. The X-axis
demonstrated the CFU levels of Candida detected in the sub-
jects, and the Y-axis showed the frequencies of the subject rate
in the percentages. No Candida colonization was detected in half
of the erythematous sign-free patients, and the distribution was
gradually decreased according to the increase of Candida CFU.
Comparatively, the peak was seen in the 11—100 CFU in the
patients with erythematous signs. The swab method was used to
obtain the samples. In this method, the surface of the dorsum of
the tongue is swabbed 10 times with a cotton swab (Eiken
Chemical Co., Ltd., Tokyo, Japan), and then the swab is directly
inoculated onto a CHROMagarTM Candida culture plate (Chroma-
gar microbiology, Paris, France). The number of Candida colonies
on the agar is counted after incubation at 30 8C for 48 h and is
expressed as CFU/swab.
Management of dry mouth in Sjo¨gren’s syndrome 121[42]. Therefore, even if Candida does not proliferate to high
levels, oral candidiasis can develop as a result of the altera-
tions in the human host defenses, such as hyposalivation,
which increases the risk of Candida colonization.
Candida colonization in Sjo¨gren’s syndrome
There is an inverse relationship between salivary flow and
oral Candida colonization [43—45]. A similar relationship
between salivary flow and candidiasis was observed in the
Dry Mouth Clinic at Tsurumi University Dental Hospital.
Out of 2678 patients (male:female = 446:2232, mean
age = 66.8), 1548 (57.8%) had oral colonization by Candida.
To examine the relationship between salivary flow and Can-
dida colonization at our institution, study subjects were
divided into 5 groups according to their level of salivation
(Table 4). We measured the WRS and WSS, and hyposalivation
was defined as a WRS less than 1.5 ml/15 min and/or WSS less
than 10 ml/10 min. The highest CFU for Candida was
observed in patients with Sjo¨gren’s syndrome (Group I),
followed by non-Sjo¨gren’s syndrome patients with decreased
WRS and WSS (Group II), patients with only decreased WRS
(Group III), patients with only decreased WSS (Group IV), and
a group with WRS and WSS within the normal limits (Group V).
These results suggest that hyposalivation is a risk factor for an
increase of Candida CFU, especially in Sjo¨gren’s syndrome
patients. Although the reason why Sjo¨gren’s syndrome
patients showed the highest CFU has not yet been elucidated,
alterations in the salivary composition might be related to
the observed Candida colonization [46,47]. The results also
suggest that unstimulated saliva flow contributed more to an
increase of Candida CFU than the stimulated saliva flow,
because there were more Candida colonies in Group III than
Group IV. An increase of Candida CFU due to hyposalivation
may possibly lead to the onset of oral candidiasis.
Diagnosis of candidiasis
Oral candidiasis is classified into three major variants based
on the clinical manifestation; pseudomembranous, erythe-
matous (atrophic) and hyperplastic [48]. A diagnosis of can-
didiasis is based on the clinical findings and is supported by
the identification of blastospores and pseudohyphae in stain-
ing smears from a lesion, identification of colonies by culture
on Sabouraud’s medium, or by histological examination [49].
Although an interpretation of the results of a microbial
examination is often complicated because Candida is presentTable 4 The relationship between the saliva flow rate and Cand
n Age WRS 
Mean  SD Mean  SD 
Group I 176 66.6  12.0 0.35  0.49 
Group II 916 69.4  11.9 0.51  0.45 
Group III 475 68.6  12.8 0.85  0.47 
Group IV 237 66.0  12.9 2.98  1.56 
Group V 874 63.1  14.5 4.12  2.58 
Total 2678
Group I, Sjo¨gren’s syndrome; Group II, non-Sjo¨gren’s syndrome with dec
decreased WSS; Group V, WRS and WSS within the normal limits.as a commensal organism in the oral cavities of up to 40% of
individuals [48], fungal examination is helpful to distinguish
candidiasis from non-specific stomatitis due to the hyposa-
livation. The occurrence of signs of erythematous candidia-
sis, such as atrophy of lingual papilla and redness of the oral
mucosa was significantly higher in patients who had Candida
detected in their mouths than in those that did not [50]. Such
a relationship has been recognized previously in the litera-
ture [51]. A fungal examination is then needed to support the
diagnosis.ida colonization in xerostomia patients.
WSS Candida Candida CFU/swab
Mean  SD (% detection) Mean  SD
4.2  3.1 85.2 316.8  1046.2
5.8  2.6 72.3 179.4  574.7
14.4  3.9 55.2 136.6  1403.4
7.8  2.0 51.5 55.9  328.1
16.9  5.0 41.2 31.7  229.6
reased WRS and WSS; Group III, only decreased WRS; Group IV, only
122 Y. NakagawaEstablishing the cut-off point for the Candida
swab test in xerostomia patients
A study was performed to examine the relationship
between Candida CFU and the morbidity of erythema in
the oral mucosa [52]. The subjects included both non-
Sjo¨gren’s syndrome and Sjo¨gren’s syndrome patients.
The histogram demonstrated the differences in patient
distribution between the two groups (Fig. 5). No Candida
was detected in 50% of the erythematous sign-free
patients, and the distribution was gradually decreased
according to the increase of Candida CFU. Comparatively,
a peak was seen in the 11—100 CFU in the patients with
erythematous signs, indicating that the morbidity of the
symptoms was positively correlated with an increase of
Candida CFU and the intersection of the curve that con-
nected the top of each frequency in the histogram sug-
gested the cut-off value that separates the erythematous
sign group and sign-free group.
A receiver operating characteristics (ROC) analysis was
used to define the best Candida cut-off score to estimate the
morbidity of erythema (redness of mucosa) in the dry mouth
patients. The optimum cut-off was 9 CFU, with the area
under the ROC curve being 0.728, in which the sensitivity
and specificity were 69% and 62%, respectively. The establish-
ment of a cut-off point will be helpful for the daily oral care
of dry mouth patients in order to prevent the risk of erythe-
matous candidiasis.
Conclusion
In this review, we described the recent improvements in the
symptomatic therapy and also the associated improvement in
the QOL that have been achieved in patients with Sjo¨gren’s
syndrome by comprehensively treating both the oral candi-
diasis and neuropsychiatric symptoms.
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